🏛️ Verified NIH Record • Updated 2026-03-23
Study to Evaluate Safety, Tolerability and Pharmacokinetics of IDB-011 (NCT06925919)
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety Tolerability and Pharmacokinetics of IDB-011 (IDB-774+IDB-898) in Healthy Adults
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: IDBiologics, Inc.
🩺 Plain-English Summary (8th-Grade Level)
Phase 1 randomized, double-blind, placebo-controlled trial to evaluate safety, tolerability, pharmacokinetics (PK) and immunogenicity of IDB-011 following intramuscular (IM )administration of single ascending doses to healthy adult participants.
Who can join: Review the eligibility criteria below.
Location: Altasciences Clinical Los Angeles — Cypress, California
Age range: 18 Years to 64 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Altasciences Clinical Los Angeles — Cypress, California
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Rift Valley Fever
- Phase 2 Safety and Immunogenicity Study of Rift Valley Fever Vaccine — Fort Deterick, Maryland
Explore by condition: All Rift Valley Fever clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.